Alpha 2.0
Login Register
» Articles » PMID: 27581614

The Journey of Personalizing Gastric Cancer Treatment

Overview
Journal Chin J Cancer
Publisher Biomed Central
Specialty Oncology
Date 2016 Sep 2
PMID 27581614
Citations 10
Authors
Li Yan
Affiliations
Soon will be listed here.
Abstract

Gastric cancer ranks the fourth most prevalent malignancy yet it is the second leading cause of cancer-related death. Every year, gastric cancer adds nearly 1 million new cancer cases, and 723,000 or 10% of cancer deaths to the global cancer burden. Approximately, 405,000 or 43% of the new cases and 325,000 or 45% of the deaths are in China, making gastric cancer a particularly challenging malignancy. This thematic series discusses the molecular classifications of gastric cancer by the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) as well as the implications in personalized therapeutic choices; discusses the evolution of gastric surgery and presents perspectives on surgical techniques in treating gastric cancer; and reviews current and emerging targeted agents as well as immunotherapies in treating gastric cancer. With these advancements in molecular characterization, surgical intervention, and targeted and immunotherapies, gastric cancer will enter a personalized medicine era in the next 5 years.

Citing Articles

Competing endogenous RNA network characterization of lymph node metastases in Leuran gastric cancer subtypes.

Liang T, Cheng M, Lu L, Liu R J Cancer Res Clin Oncol. 2023; 149(17):16043-16053.

PMID: 37688630 DOI: 10.1007/s00432-023-05382-x.

Targeting the E3 ligase NEDD4 as a novel therapeutic strategy for IGF1 signal pathway-driven gastric cancer.

Wang K, Yu Y, Wang W, Jiang Y, Li Y, Jiang X Oncogene. 2023; 42(14):1072-1087.

PMID: 36774408 PMC: 10063445. DOI: 10.1038/s41388-023-02619-4.

Co-Expression of LGR5 and CD133 Cancer Stem Cell Predicts a Poor Prognosis in Patients With Gastric Cancer.

Wattanawongdon W, Bathpho T, Tongtawee T Turk J Gastroenterol. 2021; 32(3):261-268.

PMID: 34160355 PMC: 8975476. DOI: 10.5152/tjg.2021.20108.

Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).

Qin S, Ji J, Xu R, Wang W, Tang Y, Bi F Oncologist. 2021; 26(9):e1567-e1580.

PMID: 34003545 PMC: 8417850. DOI: 10.1002/onco.13826.

CDC37L1 acts as a suppressor of migration and proliferation in gastric cancer by down-regulating CDK6.

Li L, Tao X, Li Y, Gao Y, Li Q J Cancer. 2021; 12(11):3145-3153.

PMID: 33976724 PMC: 8100790. DOI: 10.7150/jca.56097.

References
1.
Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29. DOI: 10.3322/caac.21208. View
2.
Chen W, Zheng R, Zeng H, Zhang S . The updated incidences and mortalities of major cancers in China, 2011. Chin J Cancer. 2015; 34(11):502-7. PMC: 4593358. DOI: 10.1186/s40880-015-0042-6. View
3.
Ye X, Yu C, Aggarwal A, Reinhard C . Genomic alterations and molecular subtypes of gastric cancers in Asians. Chin J Cancer. 2016; 35:42. PMC: 4862075. DOI: 10.1186/s40880-016-0106-2. View
4.
Chen T, Xu X, Zhou P . Emerging molecular classifications and therapeutic implications for gastric cancer. Chin J Cancer. 2016; 35:49. PMC: 4896142. DOI: 10.1186/s40880-016-0111-5. View
5.
Shiozaki H, Shimodaira Y, Elimova E, Wadhwa R, Sudo K, Harada K . Evolution of gastric surgery techniques and outcomes. Chin J Cancer. 2016; 35(1):69. PMC: 4962398. DOI: 10.1186/s40880-016-0134-y. View